Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis C | 12 | 2025 | 246 | 3.450 |
Why?
|
| HIV Infections | 21 | 2025 | 2941 | 2.050 |
Why?
|
| Mass Screening | 11 | 2025 | 1292 | 1.970 |
Why?
|
| Hepacivirus | 9 | 2025 | 238 | 1.420 |
Why?
|
| Pre-Exposure Prophylaxis | 6 | 2025 | 225 | 1.320 |
Why?
|
| Anti-HIV Agents | 6 | 2025 | 835 | 1.250 |
Why?
|
| Drug Users | 1 | 2024 | 42 | 0.830 |
Why?
|
| Emergency Service, Hospital | 10 | 2025 | 2116 | 0.710 |
Why?
|
| Substance Abuse Treatment Centers | 1 | 2020 | 47 | 0.650 |
Why?
|
| Tenofovir | 2 | 2020 | 275 | 0.620 |
Why?
|
| Emtricitabine | 1 | 2020 | 204 | 0.600 |
Why?
|
| Continuity of Patient Care | 2 | 2019 | 281 | 0.490 |
Why?
|
| Coinfection | 2 | 2021 | 137 | 0.490 |
Why?
|
| HIV | 3 | 2022 | 246 | 0.480 |
Why?
|
| Choice Behavior | 1 | 2016 | 172 | 0.430 |
Why?
|
| Patient Preference | 1 | 2016 | 195 | 0.410 |
Why?
|
| Sexual Health | 2 | 2024 | 59 | 0.400 |
Why?
|
| Opioid-Related Disorders | 1 | 2020 | 544 | 0.380 |
Why?
|
| Fasciola hepatica | 1 | 2012 | 2 | 0.380 |
Why?
|
| Fascioliasis | 1 | 2012 | 3 | 0.370 |
Why?
|
| Topography, Medical | 1 | 2012 | 11 | 0.370 |
Why?
|
| Viral Load | 1 | 2014 | 495 | 0.370 |
Why?
|
| Anti-Retroviral Agents | 1 | 2014 | 244 | 0.370 |
Why?
|
| Syphilis | 2 | 2024 | 33 | 0.360 |
Why?
|
| Hospitalization | 4 | 2025 | 2235 | 0.340 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2024 | 858 | 0.330 |
Why?
|
| Adult | 21 | 2025 | 38201 | 0.320 |
Why?
|
| Humans | 38 | 2025 | 138651 | 0.320 |
Why?
|
| Patient Compliance | 1 | 2014 | 598 | 0.320 |
Why?
|
| RNA, Viral | 3 | 2025 | 684 | 0.310 |
Why?
|
| Middle Aged | 18 | 2025 | 33604 | 0.290 |
Why?
|
| Antiviral Agents | 3 | 2025 | 735 | 0.270 |
Why?
|
| Prospective Studies | 7 | 2025 | 7554 | 0.270 |
Why?
|
| Male | 25 | 2025 | 68260 | 0.270 |
Why?
|
| Colorado | 4 | 2024 | 4555 | 0.250 |
Why?
|
| Female | 23 | 2025 | 73763 | 0.240 |
Why?
|
| Prevalence | 2 | 2022 | 2727 | 0.220 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2024 | 90 | 0.220 |
Why?
|
| HIV-1 | 3 | 2021 | 886 | 0.220 |
Why?
|
| Mycoplasma genitalium | 1 | 2023 | 3 | 0.210 |
Why?
|
| Urethritis | 1 | 2023 | 5 | 0.210 |
Why?
|
| Proctitis | 1 | 2023 | 7 | 0.210 |
Why?
|
| Mycoplasma Infections | 1 | 2023 | 16 | 0.210 |
Why?
|
| Uterine Cervicitis | 1 | 2023 | 8 | 0.210 |
Why?
|
| Pelvic Inflammatory Disease | 1 | 2023 | 12 | 0.210 |
Why?
|
| Trench Fever | 1 | 2022 | 5 | 0.200 |
Why?
|
| Bartonella quintana | 1 | 2022 | 5 | 0.200 |
Why?
|
| Endocarditis | 1 | 2022 | 38 | 0.190 |
Why?
|
| Lymphedema | 1 | 2021 | 23 | 0.180 |
Why?
|
| Homosexuality, Male | 2 | 2021 | 193 | 0.180 |
Why?
|
| Housing | 1 | 2022 | 142 | 0.180 |
Why?
|
| Cost-Benefit Analysis | 1 | 2024 | 608 | 0.170 |
Why?
|
| Patient Selection | 1 | 2024 | 676 | 0.170 |
Why?
|
| Focus Groups | 1 | 2024 | 539 | 0.170 |
Why?
|
| Safe Sex | 1 | 2020 | 24 | 0.170 |
Why?
|
| Particulate Matter | 1 | 2023 | 315 | 0.170 |
Why?
|
| Qualitative Research | 2 | 2025 | 1455 | 0.160 |
Why?
|
| United States | 7 | 2025 | 14938 | 0.160 |
Why?
|
| Health Services Accessibility | 2 | 2024 | 989 | 0.160 |
Why?
|
| Community Health Centers | 1 | 2019 | 63 | 0.150 |
Why?
|
| Syphilis Serodiagnosis | 1 | 2019 | 4 | 0.150 |
Why?
|
| Treponema pallidum | 1 | 2019 | 8 | 0.150 |
Why?
|
| Health Plan Implementation | 1 | 2020 | 145 | 0.150 |
Why?
|
| Hospitals | 1 | 2024 | 695 | 0.150 |
Why?
|
| Darunavir | 1 | 2019 | 19 | 0.150 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2019 | 32 | 0.150 |
Why?
|
| Self-Management | 1 | 2021 | 192 | 0.150 |
Why?
|
| HIV Protease Inhibitors | 1 | 2019 | 68 | 0.140 |
Why?
|
| Drug Prescriptions | 1 | 2020 | 259 | 0.140 |
Why?
|
| Administration, Oral | 1 | 2020 | 788 | 0.140 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2019 | 69 | 0.140 |
Why?
|
| Public Health Surveillance | 1 | 2018 | 82 | 0.130 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2020 | 282 | 0.130 |
Why?
|
| Time-to-Treatment | 1 | 2019 | 213 | 0.130 |
Why?
|
| Referral and Consultation | 2 | 2024 | 793 | 0.130 |
Why?
|
| Reproductive Health | 1 | 2018 | 90 | 0.130 |
Why?
|
| Electronic Health Records | 1 | 2024 | 1092 | 0.130 |
Why?
|
| Treatment Outcome | 3 | 2023 | 10923 | 0.130 |
Why?
|
| Attitude of Health Personnel | 1 | 2024 | 1157 | 0.120 |
Why?
|
| Antibodies, Viral | 1 | 2020 | 649 | 0.120 |
Why?
|
| Program Evaluation | 1 | 2020 | 916 | 0.120 |
Why?
|
| Ribavirin | 1 | 2016 | 82 | 0.120 |
Why?
|
| Sexual and Gender Minorities | 1 | 2019 | 229 | 0.110 |
Why?
|
| Hepatitis C, Chronic | 1 | 2016 | 145 | 0.110 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 5112 | 0.110 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2014 | 280 | 0.100 |
Why?
|
| Algorithms | 1 | 2021 | 1740 | 0.100 |
Why?
|
| Primary Health Care | 2 | 2023 | 1777 | 0.100 |
Why?
|
| Risk Factors | 4 | 2024 | 10252 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 849 | 0.090 |
Why?
|
| Cohort Studies | 2 | 2019 | 5697 | 0.090 |
Why?
|
| Delivery of Health Care | 2 | 2021 | 958 | 0.090 |
Why?
|
| Life Cycle Stages | 1 | 2012 | 41 | 0.090 |
Why?
|
| Adolescent | 5 | 2024 | 21564 | 0.090 |
Why?
|
| Africa | 1 | 2012 | 118 | 0.090 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 1323 | 0.090 |
Why?
|
| Sofosbuvir | 2 | 2022 | 59 | 0.090 |
Why?
|
| Retrospective Studies | 5 | 2025 | 15909 | 0.090 |
Why?
|
| Travel | 1 | 2012 | 134 | 0.080 |
Why?
|
| Population Surveillance | 1 | 2014 | 476 | 0.080 |
Why?
|
| Sexual Partners | 2 | 2024 | 187 | 0.080 |
Why?
|
| Socioeconomic Factors | 1 | 2014 | 1296 | 0.080 |
Why?
|
| Time Factors | 2 | 2025 | 6851 | 0.080 |
Why?
|
| Young Adult | 5 | 2024 | 13305 | 0.070 |
Why?
|
| Aged | 2 | 2019 | 24024 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2021 | 1941 | 0.060 |
Why?
|
| Organizational Case Studies | 1 | 2025 | 78 | 0.060 |
Why?
|
| New Orleans | 1 | 2024 | 14 | 0.050 |
Why?
|
| Demography | 1 | 2024 | 296 | 0.050 |
Why?
|
| Macrolides | 1 | 2023 | 67 | 0.050 |
Why?
|
| Triage | 1 | 2025 | 241 | 0.050 |
Why?
|
| Ambulatory Care Facilities | 1 | 2024 | 245 | 0.050 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2023 | 184 | 0.050 |
Why?
|
| Polyphosphates | 1 | 2022 | 43 | 0.050 |
Why?
|
| Anthropology, Cultural | 1 | 2021 | 21 | 0.050 |
Why?
|
| Intention to Treat Analysis | 1 | 2021 | 76 | 0.040 |
Why?
|
| Pregnancy | 2 | 2024 | 6829 | 0.040 |
Why?
|
| Dried Blood Spot Testing | 1 | 2022 | 121 | 0.040 |
Why?
|
| Nasopharynx | 1 | 2021 | 72 | 0.040 |
Why?
|
| Community-Based Participatory Research | 1 | 2022 | 160 | 0.040 |
Why?
|
| Fluorenes | 1 | 2020 | 45 | 0.040 |
Why?
|
| Genotype | 1 | 2025 | 1842 | 0.040 |
Why?
|
| Protease Inhibitors | 1 | 2020 | 105 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 5520 | 0.040 |
Why?
|
| Alanine | 1 | 2020 | 152 | 0.040 |
Why?
|
| Specimen Handling | 1 | 2021 | 180 | 0.040 |
Why?
|
| Saliva | 1 | 2021 | 238 | 0.040 |
Why?
|
| Public Health | 1 | 2024 | 580 | 0.040 |
Why?
|
| Benzimidazoles | 1 | 2020 | 181 | 0.040 |
Why?
|
| Length of Stay | 1 | 2025 | 1238 | 0.040 |
Why?
|
| Reagins | 1 | 2019 | 1 | 0.040 |
Why?
|
| Oxazines | 1 | 2019 | 30 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2021 | 1044 | 0.040 |
Why?
|
| Research Design | 1 | 2024 | 1118 | 0.040 |
Why?
|
| Adenine | 1 | 2020 | 301 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2022 | 898 | 0.040 |
Why?
|
| Chicago | 1 | 2018 | 61 | 0.030 |
Why?
|
| Pyridones | 1 | 2019 | 170 | 0.030 |
Why?
|
| Piperazines | 1 | 2019 | 345 | 0.030 |
Why?
|
| Logistic Models | 1 | 2021 | 2065 | 0.030 |
Why?
|
| Community Health Services | 1 | 2018 | 228 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2025 | 3433 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 1032 | 0.030 |
Why?
|
| Physicians | 1 | 2024 | 932 | 0.030 |
Why?
|
| Animals | 2 | 2021 | 37217 | 0.030 |
Why?
|
| Caregivers | 1 | 2021 | 904 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2019 | 1765 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2023 | 1818 | 0.020 |
Why?
|
| Parents | 1 | 2021 | 1421 | 0.020 |
Why?
|
| Child | 2 | 2021 | 21921 | 0.020 |
Why?
|